The short version
- The Indian government has imposed a 30% margin cap on 137 cancer drugs after the supreme court condemned previous pricing practices as extortionate.
- Official estimates suggest the measure could reduce medicine prices by up to 70%, potentially saving patients billions of rupees annually and improving access to treatment.
- Critics warn that hospitals may circumvent the cap by increasing charges for other services, highlighting the need for broader systemic transparency in healthcare supply chains.
The Indian government has announced a significant reduction in the cost of cancer medications, extending price controls to 137 drugs starting next month. This policy shift follows a landmark intervention by the supreme court, which ruled that excessive mark-ups imposed by hospitals and retailers on life-saving medicines constituted extortion. The move aims to address a long-standing crisis where high drug prices force low-income families into debt or compel them to forgo essential treatment entirely.
The legal pressure originated from a petition filed in 2022 by Sarojam Radhakrishnan, a retired bank clerk from Kerala diagnosed with breast cancer. Her family could not afford the monthly cost of targeted treatments, which exceeded 63,000 rupees. Recognizing that thousands of households faced similar financial devastation, Radhakrishnan sought government intervention to lower costs. The case eventually reached the supreme court, where justices examined the pricing structures across the healthcare supply chain.
During hearings in late September, judges Vikram Nath and Sandeep Mehta highlighted stark disparities between wholesale and retail prices. They noted that a cancer drug supplied to hospitals for 2,700 rupees was often sold to patients for 27,000 rupees. Analysis by the National Pharmaceutical Pricing Authority revealed that trade mark-ups on certain cancer drugs averaged 170%, with some instances exceeding 700%. The court described this situation as carnage, emphasizing the disproportionate profits enjoyed by distributors and chemists at the expense of patients.
In response to these findings, the Department of Pharmaceuticals has expanded an existing 30% margin cap, previously applied to only 42 drugs, to cover 137 additional medications. Officials project that this measure will reduce medicine prices by up to 70%. The government estimates that cancer patients could save approximately 2,500 crore rupees annually, significantly lowering out-of-pocket expenses. This intervention targets a critical vulnerability in India’s healthcare system, where medical costs push an estimated 55 million people below the poverty line each year.
The financial burden of cancer treatment has created a culture of fear among low-income populations. Krishan Kalra, a former council member of the Rajiv Gandhi Cancer Institute and Research Centre, observes that many workers avoid free diagnostic camps in Gurgaon due to anxiety about potential costs. Patients often prefer remaining unaware of their health status rather than facing the prospect of unaffordable treatment. This avoidance behavior undermines early detection efforts, which are crucial for successful outcomes.
Current insurance coverage remains insufficient for many families. The government’s Ayushman Bharat scheme provides annual cover of 500,000 rupees per family, which may only afford a single dose of certain expensive drugs like Kadcyla used for breast cancer. Patients often require up to 14 doses, leaving them exposed to catastrophic expenses. Dr. Ravi Kannan, an oncologist in Assam, notes that many families begin treatment but abandon chemotherapy or radiation when they can no longer sustain the financial strain.
India faces a growing public health challenge with approximately 1.56 million new cancer cases recorded annually, up from 1.39 million in 2020. While the price cap is a welcome step for improving access, experts warn that it may not be sufficient without broader reforms. Jyotsna Singh of the Working Group on Access to Medicines and Treatments argues for a total overhaul of the healthcare system to ensure transparency from manufacturing to point of sale.
Concerns remain regarding potential loopholes in the new regulations. Hospitals and pharmaceutical companies might attempt to offset lower drug margins by raising charges for other services or items. The supreme court has also questioned why the cap applies exclusively to cancer drugs, suggesting that similar protections may be needed for other medical treatments. As the government implements these changes, monitoring will be essential to ensure that the intended savings reach patients without being eroded by indirect cost increases.
Sources behind this briefing
Go to the original reporting
- The Guardian US↗India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’
